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Abstract—In this paper, we study a novel problem: “auto-
matic prescription recommendation for PD patients.” To realize
this goal, we first build a dataset by collecting 1) symptoms
of PD patients, and 2) their prescription drug provided by
neurologists. Then, we build a novel computer-aided prescription
model by learning the relation between observed symptoms
and prescription drug. Finally, for the new coming patients,
we could recommend (predict) suitable prescription drug on
their observed symptoms by our prescription model. From the
methodology part, our proposed model, namely Prescription
viA Learning lAtent Symptoms (PALAS), could recommend
prescription using the multi-modality representation of the data.
In PALAS, a latent symptom space is learned to better model the
relationship between symptoms and prescription drug, as there
is a large semantic gap between them. Moreover, we present
an efficient alternating optimization method for PALAS. We
evaluated our method using the data collected from 136 PD
patients at Nanjing Brain Hospital, which can be regarded as
a large dataset in PD research community. The experimental
results demonstrate the effectiveness and clinical potential of our
method in this recommendation task, if compared with other
competing methods.
Index Terms—Computer-Aided Prescription, Latent Symptom
Space, Multi-Modality Learning, Multi-Label Learning
I. INTRODUCTION
PARKINSON’S Disease (PD)1 is a chronic and progressiveneurological disorder that associated with symptoms such
as trouble of moving and sleeping, tremor, shaking, dizziness,
and fainting. It is now believed as the second most common
neurodegenerative disease, affecting nearly one million people
in US [15]. Though researches show that PD might be related
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to genetic and environmental factors, the exact cause of PD is
still remained unknown [24].
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Fig. 1: The proposed PALAS model.
In recent years, aiming to guide better intervention therapy,
computer-aided methods for PD patients have aroused lots
of research interests [1][6][7][9][15][16][17][20][21][31]. All
these researches are focusing on computer-aided diagnosis,
which is used to predict whether a patient belongs to PD in
the early stage. To the best of our knowledge, the study of
computer-aided prescription for PD has seldom been touched,
whose goal is to choose the suitable treatment drugs for PD
patients based on their observed symptoms. Motivated by the
success application of artificial intelligence in various studies,
we in this paper investigate a novel problem: “automatically
recommend the suitable drugs for PD patients according to
their observed symptoms.”
This prescription recommendation (or prediction) task is
clinically meaningful and practically feasible. In conventional
human-based prescription, we require professional experience
of a neurologist to prescribe medication for a PD patient.
Unfortunately, medical treatment for PD is very much per-
sonalized. In reality, different neurologists usually prescribe
different treatment drugs according to their own experience
and judgement. Furthermore, if other factors such as prices and
hidden side effects of drugs are considered, seeking a (near)
optimal prescription for each individual patient would become
even more complicated and difficult. Thus, a data-driven drug
prescription, generated by machine learning technique that
incorporates previous human-based prescription results, will
be very helpful, and can be used as a guidance or reference,
especially when there is a large diversity of views among
different neurologists.
To realize this goal, firstly, we have spent two years to
collect the motor and non-motor symptoms from 136 PD
patients, which could be regarded as a large population in
PD research community. Basically, the motor symptoms record
the daily body-movement of the subjects, while the non-motor
symptoms describe the mental states of the subjects, such as
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2impression, psychology, etc.All these PD patients also have
their symptoms improved after clinical treatment, where the
drugs used in the successive treatment are recorded. These
information could be used to evaluate the performance of
computer-aided prescription using the human-based prescrip-
tions as the ground truth. 2
Secondly, using the recorded data from the observed motor
and non-motor symptoms, we combine feature-based and
similarity-based representations to obtain a multi-modality
representation.
Finally, for prediction, we propose a novel model called
Prescription viA Learning lAtent Symptoms (PALAS) (see
Figure 1), which is inspired and motivated by the following
observations:
• Sparse drug label. One single type of drug can relieve
only a small amount of all symptoms. Also, it is very
rare to have a patient that is prescribed with all kinds of
treatment drugs. Instead, most patients would only take
a very few from all the candidates of treatment drugs,
making the drug labels for each subject being sparse.
• Large semantic gap. There indeed exists a large se-
mantic gap between the observed symptoms and the
treatment drugs which requires professional experience
from a clinician to understand. Therefore, the relation of
symptoms and drug labels should not be modeled directly
as it may limit the performance of the prediction model.
Our proposed model PALAS is able to address the above
mentioned issues by learning a latent symptom space that ex-
ploits the intrinsic symptom-to-drug connection. Specifically,
based on the latent symptom space, we introduce a truncated
objective to jointly learn (1) the observed symptoms -to-
latent symptoms connection and (2) latent symptoms -to- drug
labels connection. Also, we impose a sparse regularizer as a
constraint to guarantee the sparsity of drug label. Moreover,
considering the limited number of subjects in our study, we
employ a transductive setting to incorporate all the valuable
data to train a better model. In other words, we also use the
observed features (not including labels) of the testing data
in PALAS. We solve PALAS effectively using an alternating
optimization algorithm, and analyze its convergence.
Our contributions in this paper are summarized as follows:
1) Our work is the first attempt to combine the observed motor
and non-motor symptoms to recommend/predict the suitable
treatment drugs for PD patient as a data-driven reference. 2) To
leverage various observed symptoms, we propose to use multi-
modality representation that incorporates both the feature-
based and similarity-based representations of the observed
symptoms. 3) To address the large semantic gap between the
observed symptoms and the prescription drugs, as well as to
better capture the intrinsic symptom-to-drug relationship, we
propose PALAS model that learns a latent symptom space
linking the observed symptoms and the prescription drugs.
2Note that in Figure 1, drug label is a binary matrix with rows as patients
and columns as drugs to record if current patient takes a certain drug (i.e., 1
indicates yes and 0 indicates no).
II. RELATED WORKS
Recently, several works have been developed for computer-
aided PD diagnosis. Hirschauer et al .[15] employed an en-
hanced probabilistic neural network that integrated various
features to diagnose whether a subject belongs to PD or
healthy control (HC). Oliveira et al .[21] used voxel-wise
features extracted from the SPECT images for PD/HC predic-
tion. Using MRI data after registration [47], Singh et al .[31]
combined self-organizing map and least squares SVM for
PD diagnosis. Liu et al .[20] performed iterative canonical
correlation analysis to analyze different brain regions through
T1-weighted MR images. Adeli et al .[1] distinguished PD
and HC using MRI data with a joint feature-sample selection
method. Lei et al .[16] proposed a multitask learning-based
framework to model the relation between multiple modalities
(e.g., sample, feature, and clinical scores) for PD diagnosis.
Also, a deep learning-based multimodal assessment of PD was
developed in [9]. In [43], a method of using machine learning
tools on voice signal was introduced for Parkinson’s disease
detection. Also, a mobile application was developed in [44]
to detect and identify the motor disorders. To assess brain
connectivity dynamics and investigate the connectivity way,
Cai et al .[6] introduced the dynamic graph as a theoretical
tool to model and analyze the functional connectivity in PD.
All these aforementioned methods were used to address the
PD diagnostic problem, while the computer-aided prescription
was rarely addressed, if it has ever been explored before.
Moreover, as for another representative neurodegenerative
disease, Alzheimer’s disease (AD), several computer-aided
methods have been developed in recent years. The common
goal of these methods is to learn a common space from
multi-view/modal data to aid the diagnosis. For example, in
[36], a multi-view algorithm was introduced by automatically
learning the best combination of multiple kernels. In [38],
Zhang et al .proposed to use a shared tree-structured model
to investigate the genetic risk factors for AD treatment. In
[37], a method was developed to combine individual sub-
networks of brain connectivity for MCI diagnosis. Also, Xu
et al .[39] utilized a sparse model under low-rank constraint
for cognitive assessment prediction for AD patients. Kim et
al .[40] presented a multi-modal extreme learning machine
to integrate different imaging modalities. Shi et al .[27][28]
proposed to use the coupled features and coupled boosting for
multi-view data analysis for AD diagnosis. Tong et al .[41]
analyzed complementary relation between multiple modalities
and present a diagnosis model for AD. The incomplete neu-
roimaging and genetic data was combined for AD diagnosis
in [50]. Please note that, these methods for AD focus on the
binary or small-sized classification problem while our method
deals with multi classification problem (i.e., number of class
is 31) which is more challenging. In addition, several methods
[48][49] for brain activity analysis are also related to our
works.
Furthermore, from the methodology perspective, our study
is related to multi-view learning methods, e.g., co-training
style algorithms [4][30], multi-kernel learning methods
[2][23], and subspace learning methods [14][22], which learn
3the intrinsic or consensus representation from different views
of data (or modalities) [33]. Also, from the perspective of
selecting the (near) optimal drugs, our task is related to multi-
label learning where each sample is associated with a set
of labels, such as in problem transformation [5][13], and
algorithm adaptation [8][11][34].
Indeed, among these works, our proposed PALAS model is
closest to [12][35], which considered multi-modality features
and multiple labels simultaneously. In particular, Fang et
al .presented a method [12] to learn a multi-modality con-
sensus representation for image classification, which imposes
a maximum margin criterion to improve the generalization
ability. For image annotation task, Zou et al .developed a
method called MVML [35] by combining multiple single-label
learners in a boosting framework with the base learner as a
modified multi-modality based SVM. However, the prediction
performance is very limited if we directly utilize [12][35] for
our study as (1) the intrinsic symptom-to-drug connection is
not considered, and (2) the sparse property of drug label matrix
is ignored. We will further discuss this using our experimental
results in Section V.
In brief, our problem is novel as it is fundamentally different
from the previous computer-aided PD diagnosis works. In
addition, the related works in multi-view learning and multi-
label learning could not be efficiently applied to our problem.
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Gender:
Age:  Male, 62.5%                  Female, 37.5%
Severity:
        Non-severe, 84.6%           Severe, 15.4%
 85/136                              51/136
 115/136                              21/136
Fig. 2: The demographic information of all the PD patients.
III. DATA COLLECTION AND REPRESENTATION
A. Data Collection
We spent two years to build up a dataset of 136 PD
inpatients in Nanjing Brain Hospital (NBH), China, under
Ethical Approval 2015-KY-041 from the Ethics Committee of
NBH, in accordance with the Principles of the Declaration of
Helsinki. All of the 136 inpatients were fully informed about
the research, and agreements were signed prior to the initiation
of the research. Figure 2 summarizes the demographic infor-
mation and the severity of PD symptoms of the 136 inpatients.
The diagnosis and treatment of the inpatients observed the
UK PD Society Brain Bank Clinical Diagnostic Criteria. In
the following, we will first describe a general diagnosis and
treatment procedure for any individual inpatient. Then, we will
detail the medical scales, symptoms, and drugs considered in
this research.
General procedure. Upon the admission of an inpatient,
the symptoms are evaluated using a medical scale. The eval-
uation results are recorded as the symptoms matrix x. The
neurologists shall then start an initial drug therapy for the
inpatient. Within the next 1 to 2 weeks, the therapy might be
adjusted based on the clinical observations and feedback from
the inpatient. After that, the inpatient is kept under observation
with the adjusted therapy for 1 month. The adjusted therapy
becomes a drug label y and the symptom-drug pair (x,y)
is added to the dataset if and only if the symptoms x are
eventually alleviated using the drugs y.
Symptoms and the medical scale. We adopt multiple
widely used medical scales for thorough evaluations of the
symptoms, including Unified PD Rating Scale (UPDRS),
Non-Motor Symptoms Questionnaire (NMS-Quest), The PD
Sleep Scale (PDSS), Hamilton Depression Scale (HAMD),
Parkinson’s Disease Questionnaire (PDQ), and Hamilton Anx-
iety Rating Scale (HAMA). Specifically, we consider motor
symptoms such as tremor, rigidity, hand movement, leg agility,
posture, gait, etc. as well as non-motor symptoms such as
cognition, depression, anxiety, sleep/nocturnal problems, etc.
Table II shows a full list of medical scales we used and their
targets of evaluation. Table II also shows the composition of
the 55 motor features and 143 non-motor features used in our
dataset.
Drugs. In this research, we consider 31 drugs according
to both the PD handbooks [45][46] and the clinical practice
in NBH, China, including including Cabergoline, Stilnox,
Alprazolam, Carbidopa and Levodopa, etc., which are shown
effective in improving PD by previous studies in the field. A
full list of the 31 drugs can be found in Table I. Note that
some of the drugs might not be conventionally recognized as
“PD drugs” because they are for non-motor symptoms such
as depression, anxiety, etc.
Motor symptoms. The motor symptoms normally reflect
whether a patient suffers from motor skills decline in daily
activities (see Table II). Based on the clinical observation,
medical measurement and necessary quality assurance, the
neurologists graded the symptoms according to a predefined
numerical scale. Some of the typical motor symptoms and
their corresponding numerical grading scores are described as
follows:
1) Finger tapping→ 0 (no problem), 1 (1-2 interruptions),
2 (3-5 interruptions), 3 (more than 5 interruptions), 4
(cannot perform).
2) Arising from chairs → 0 (no problem), 1 (slower than
normal), 2 (pushes self up), 3 (needs to push off ), 4
(cannot perform).
3) Swallow → 0 (normal), 1 (few bucking), 2 (occasional
bucking), 3 (only soft-diet), 4 (nasal feed).
4) Dystonia → 0 (no), 1 (yes).
5) Tetany → 0 (no), 1 (slightly), 2 (moderate), 3 (heavy),
4 (severe).
6) Using tableware→ 0 (normal), 1 (slow but without any
help), 2 (awkward and need help), 3 (need help), 4 (need
feeding).
4TABLE I: The full list of all 31 drugs used in our study.
ID: 1 ID: 2 ID: 3 ID: 4 ID: 5 ID: 6 ID: 7 ID: 8
Rasagiline Selegiline Zonisamide Safinamide Pramipexole IR/ER Rotigotine Piribedil Ropinirole IR/PR
ID: 9 ID: 10 ID: 11 ID: 12 ID: 13 ID: 14 ID: 15 ID: 16
Apomorphine Cabergoline Pergolide Entacapone Tolcapone Opicapone Carbidopa and Levodopa Istradefylline
ID: 17 ID: 18 ID: 19 ID: 20 ID: 21 ID: 22 ID: 23 ID: 24
Amantadine Artane Stilnox Vitamin E Zopiclone Coenzyme Q10 Alprazolam Bromocriptine
ID: 25 ID: 26 ID: 27 ID: 28 ID: 29 ID: 30 ID: 31
Memantine Clonazepam Donepezil Mirtazapine Quetiapine Zoloft Baclofen
Non-motor symptoms. Different from the motor symp-
toms, the non-motor symptoms do not describe movement,
coordination, physical tasks or mobility, but record the infor-
mation such as cognitive ability, mental state, and physical
condition of a subject (see Table II). Some of the typical non-
motor symptoms and their corresponding numerical grading
scores are listed as below:
1) Computing 5 simple equations, e.g., 3+7=? → 0 to 5
(according to the number of correct answers).
2) Daytime sleepiness→ 0 (no daytime sleepiness), 1 (can
resist and stay awake), 2 (fall asleep when alone and
relaxing), 3 (sometimes fall asleep), 4 (often fall asleep).
3) Leg swelling → 0 (no), 1 (yes).
4) Quality of sleeping at night → 0 to 10 (according to
the quality assessment).
5) Insomnia→ 0 (no), 1 (slightly), 2 (moderate), 3 (heavy),
4 (severe).
6) Self-depreciation → 0 (no), 1 (tell when asked), 2
(automatic tell), 3 (initiative tell), 4 (ecphronia).
The recorded numerical values are then regarded as the
feature-based representations of the observed motor and non-
motor symptoms, respectively.
TABLE II: Data features from multiple medical scales.
Medical Scale Target of Evaluation Data Features
UPDRS (Part I) Mentation, behavior and mood 4 non-motor
UPDRS (Part II) Activities of daily living 9 motor, 4 non-motor
UPDRS (Part III) Motor disability 27 motor
UPDRS (Part IV) Motor complications 11 motor
Hoehn and Yahr Score Disease severity 1 motor
NMS-Quest Various non-motor symptoms 30 non-motor
MMSE Cognition 20 non-motor
HAMD Depression 24 non-motor
HAMA Anxiety 14 non-motor
PDQ-39 Quality of life 7 motor, 32 non-motor
PDSS Sleep/nocturnal problems 15 non-motor
B. Data Representation
From the above data collection procedure, we obtained a
dataset of 136 PD inpatients. Each inpatient is represented as
a 198-dimensional symptom vector x, and is associated with
a 31-dimensional label y.
To formally record this information, we use a binary matrix
Y as the drug label matrix to denote the relationship between
the patients and the drugs. In particular, Yij = 1 if and
only if the i-th patient has taken the j-th drug, and Yij = 0
otherwise. Let X1 ∈ R(n+m)×d1 and X2 ∈ R(n+m)×d2 denote
the feature-based representations of the observed motor and
non-motor symptoms, respectively, where n and m denote
the number of training and testing samples (i.e., subjects),
respectively, and d1 and d2 denote the numbers of motor
and non-motor symptoms, respectively. According to the data
acquisition procedure discussed previously, d1 = 55 and
d2 = 143.
Besides, we also devise several similarity-based representa-
tions to reflect patient-wise similarity. Particularly, we utilize
various kernels, such as linear, Gaussian, Bhattacharyya, and
χ-square kernels to compute the similarity between any two
row feature vectors in X ∈ R(n+m)×(d1+d2), i.e., a concatena-
tion of feature matrices X1 and X2 (i.e., X = [X1,X2]). The
resulting similarity-based representations are then denoted as
Xi ∈ R(n+m)×(n+m) (∀i ≥ 3).
Both of the feature- and similarity-based representations
are then combined as the multi-modality representation
[18][26][27][51] of the observed motor and non-motor symp-
toms. In general, the multi-modality representation of the
observed symptoms for the PD patients is denoted as Xi ∈
R(n+m)×di (1 ≤ i ≤ s), where di is the feature dimensionality
of the i-th modality, and s is the total number of different
modalities. In our work, we set s as 6 (i.e., 2 feature-based
and 4 similarity-based representations).
IV. PALAS MODEL
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Fig. 3: Pearson correlation coefficient of different drugs.
A. Problem Analysis
To illustrate the complex relationship between the observed
symptoms and treatment drugs, we conduct an experiment by
treating our prescription recommendation (prediction) task as
several independent binary classification problems, and report
the results in Figure 4. Specifically, for each prescription drug
(i.e., a column vector in the drug label matrix Y), we train
a linear SVM using the observed symptoms (i.e., the feature
matrix X as described in Section III) and report the average
10-fold cross-validation classification accuracy in Figure 4.
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Fig. 4: Prediction performance of single prescription drug
using only the observed symptoms X.
As shown in Figure 4, the classification accuracy is very
low if we use only the numerical values of the observed symp-
toms to recommend/predict the prescription of a typical drug.
Moreover, such single task prediction could not utilize the
interrelation between different prescription drugs. To further
understand the interrelation, the Pearson correlation coefficient
is reported in Figure 3. We can observe the interrelation indeed
exists between different drugs.
Thus, it is more feasible and reasonable to learn all the pre-
diction tasks jointly (i.e., multi-label learning), and introduce
a latent symptom space to exploit the intrinsic symptom-to-
drug connection, so that the overall prediction performance
could be improved. Specifically, by learning a latent symptom
space, we in fact jointly learn two transformations, i.e., (1) the
observed symptoms to latent symptoms transformation, and
(2) the latent symptoms to treatment drugs transformation. The
major considerations on learning these two transformations are
given as follows:
• Observed symptoms to latent symptoms transfor-
mation. The latent symptom space is required to fully
incorporate information from different modalities (i.e.,
Xi) and should be able to well represent all the modal-
ities in multi-modality representation. In other words,
the learned latent symptom representation should have
relatively small F -norm distance with the transformation
of each individual modality.
• Latent symptoms to treatment drugs transformation.
The transformation matrix that maps the latent symptom
representation to the drug labels should be sparse, as
each prescription drug can only treat a limited number
of symptoms.
B. Problem Formulation
Given the multi-modality representation Xi ∈ R(n+m)×di
(i = 1, ..., 6 for 6 modalities) of all the samples, and the
ground truth drug label matrix Y¯ ∈ Bn×c of the n training
samples (B = {0, 1}), where c is the total number of drugs
(c = 31 in our work), our aim is to recommend/predict the
drug labels for the m test samples. For dimension consistency,
we introduce Y ∈ B(n+m)×c = [Y¯; 0] as the (expanded) drug
label matrix, in which the last m rows of Y are set to zeros
since the labels of the testing samples are not available during
the training stage
We accomplish this prediction task by proposing PALAS
model, in which a latent symptom representation P ∈
R(n+m)×k is learnt to connect the observed symptoms with
the prescription drugs, where k indicates the number of
latent symptoms. The main objective function of PALAS is
mathematically defined as follows:
arg min
Ui,P,V
F(Ui,P,V) =
s∑
i=1
(
‖XiUi −P‖2F + α‖Ui‖2F
)
+‖J(Y −PV)‖2F + β‖V‖1,
(1)
where Ui ∈ Rdi×k is the observed-to-latent symptom trans-
formation matrix to ensure that the latent symptom space P
is able to represent the i-th modality (i.e., Xi). V ∈ Rk×c is
the symptom-to-drug transformation matrix to link different
latent symptoms to different drugs. V is imposed to be
sparse, since a typical drug can only relieve a very small
number of symptoms. Also, in clinical perspective, it is rare
to have a patient that should take all the possible drugs.
J ∈ B(n+m)×(n+m) is a binary diagonal matrix denoted as
J = diag
( n︷ ︸︸ ︷
1, ..., 1,
m︷ ︸︸ ︷
0, ..., 0
)
, (2)
which is used to indicate the training samples in a transductive
setting, so that only the training samples are taking part in
the prediction loss (i.e., second term in Eq. (1)). In this way,
although the testing samples do not contribute to the drug
label prediction, they are incorporated to help learning P
and Ui, thus addressing the issue of limited samples in this
study. α and β are the regularization parameters to balance
different terms in Eq. (1). Note that, the transductive setting
belongs to a typical semi-supervised learning where the semi-
supervised setting has been recently adopted in drug prediction
or association [10][19].
C. Optimization
We employ alternating optimization strategy [29] to solve
Eq. (1) as all of its variables are jointly convex.
Update Ui with P and V fixed. We denote Ut+1i as
the transformation matrix for the i-th modality at the (t+1)-th
iteration, which can be updated from Uti (at the t-th iteration)
by utilizing the gradient descent method as follows:
Ut+1i ← Uti − ρ
(
X>i XiU
t
i −X>i P + αUti
)
, (3)
where ρ is the stepsize automatically determined by the back-
tracking line search [29].
Update V with Ui and P fixed. We can obtain the
following function H(V) by fixing Ui and P:
H(V) = ‖J(Y −PV)‖2F + β‖V‖1, (4)
which is a combination of a smooth term and a L1-norm. We
employ FISTA (Fast Iterative Soft-Thresholding Algorithm)
[3] for solving V in Eq. (4). We summarize the optimization
steps as follows:
Vt
′ ← G
(
Γt
′ − 1
lt′
∇H(Γt′)
)
,
ψt′+1 ← 1 +
√
1 + 4ψ2t′
2
,
Γt
′+1 ← Vt′ +
(ψt′ − 1
ψt′+1
)(
Vt
′ − Vt′−1
)
,
(5)
6where t′ is used to indicate the inner iteration during solving
V which is different from outer iteration t in the main
objective. Γ ∈ Rk×c is an intermediate variable initialized as
Γ1 = V0 (V0 is the initialization before performing FISTA).
ψt′ ∈ R is a variable initialized as ψ1 = 1. lt′ is the stepsize
automatically determined by the back-tracking line search.
Meanwhile, ∇H(Γt′) is the gradient at the t′-th iteration,
given as
∇H(Γt′) = −P>J
(
Y −PΓt′
)
. (6)
In Eq. (5), G is the shrinkage function, given as
G(x) =
 x−  if x > ,x+  if x < ,
0 otherwise
(7)
Thus, with fixed Ui and P, we can eventually obtain the
updated V by repeating the steps in Eq. (5) until convergence.
Update P with Ui and V fixed. To update P, we employ
gradient descent with the following updating rule:
Pt+1 ← Pt− ρ
(
J(Y−PtV)V>+
s∑
i=1
(XiUi−Pt)
)
. (8)
Finally, we summarized all the optimization steps for
PALAS model in Algorithm 1. For initialization, Ui and V
are set to
Ui =
1
dik
, (9)
and
V =
1
kc
, (10)
where 1 is the all-one matrix/vector. In addition, we perform
unsupervised PCA on X and reduce the original dimension
(i.e., d1 + d2) to k, as the initialization for P. We then
repeat Eq. (3), Eq. (5), and Eq. (8) to update Ui, V, and
P, respectively, until convergence.
Test Sample Prediction: Given a testing sample z repre-
sented by {zi ∈ Rdi} (1 ≤ i ≤ s), the predicted drug labels
yˆ ∈ Rc can be obtained by
yˆ = sgn
(1
s
s∑
i=1
ziUiV − 1
2
)
, (11)
where 1 is all-one vector.
D. Convergence Analysis
Lemma 1: [3] Let V∗ be the optimal solution of Eq. (4)
and η be the Lipschitz constant, ∀t ≥ 1,
H(Vt)−H(V∗) ≤ 2ltη‖V
0 −V∗‖2
(1 + t)2
.
Theorem 1: The optimization process (i.e., Algorithm 1)
monotonically decreases the objective of Eq. (1) in each
iteration and will converge to a local optimal solution.
Proof 1: By performing Algorithm 1, we obtain the updated
Ut+1i , P
t+1, Vt+1 from Uti, P
t, Vt in each iteration, respec-
tively. Thus, performing Eq. (3) and Eq. (8) and incorporating
Lemma 1, we get
∀t ≥ 1,F(Uti,Pt,Vt)
Eq. (3)︷︸︸︷
≥ F(Ut+1i ,Pt,Vt)
Lemma 1︷︸︸︷
≥ F(Ut+1i ,Pt,Vt+1)
Eq. (8)︷︸︸︷
≥ F(Ut+1i ,Pt+1,Vt+1).
(12)
Therefore, the convergence could be satisfied. 
Algorithm 1 Optimization of PALAS
Input: ∀iXi, Y
Initialization:
∀iUi = 1dik , V = 1kc
P← Performing PCA on X
while not converged do
∀iUi ← Update by Eq. (3).
V← Update by Eq. (5).
P← Update by Eq. (8).
end while
Output: ∀iUi, V, P
E. Complexity
To analyze the complexity of our optimization algorithm,
for each outer iteration, we denote T1 as the number of inner
iteration for solving V by repeating Eq. (5). Also, we denote
dˆ =
∑s
i=1 di, d¯ =
∑s
i=1 d
2
i . Thus, for solving all Ui (1 ≤
i ≤ s), the complexity is O(d¯k + d¯n + dˆnk); For solving
V, the complexity is O(n2kT1 + nkcT1); For solving P, the
complexity is O(n2c+nkc+ dˆnk). We denote the number of
outer iterations as T . In summary, as FISTA is fast to converge
(i.e., T1  T ), the major complexity of our optimization is
O(n2cT + dˆnkT + n2kT1T + nkcT1T ).
V. RESULTS
A. Experimental Setting
Evaluation Metrics. As our goal is to recommend/predict
the best subsets from all the treatment drugs, this belongs to a
conventional multi-label learning setting to predict the labels
of 31 drugs. Inspired by multi-label learning [34][11][8], we
employ the Hamming loss, one-error, coverage, and
ranking loss as our evaluation metrics. All of them are
the lower the better. Moreover, we report the mean accuracy,
mean sensitivity and mean specificity on different drugs for
evaluation. All of them are the higher the better. Beside these
seven metrics, we also use clinical metrics provided by three
neurologists, which we will clarify shortly.
We implemented our method in a PC with Intel i7-core
3.7GHz and 32GB RAM. In addition, we also performed 100
times of 10-fold cross-validation (i.e., 14 samples in the 1-st to
9-th folds, and 10 samples in the 10-th fold), and averaged the
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Fig. 5: The prediction performance of the PALAS model using different k values.
obtained values as the final results, to avoid possible data-split
bias.
Parameter Setting. For choosing the appropriate param-
eters, we randomly choose the 90% data as training set to
investigate the different combinations of parameters according
to their performance on the rest 10% data as testing set, which
aims to automatically determine the values of three parameters
in PALAS, i.e., α, β, and the number of latent symptoms k. In
particular, α and β are chosen from 15 different values (i.e.,
1, 0.5, 0.3, 0.1, 0.05, 0.01, 0.005, 0.001, 5 × 10−4, 10−4,
5× 10−5, 10−5, 10−6, 10−8, 10−10), while k is chosen from
10, 20, ..., 100. The combination of α, β and k that achieves
lowest value in Hamming loss on this chosen testing set is
selected as the final parameters in PALAS.
According to this parameter choosing process, the combi-
nation of α = 0.3, β = 0.1, and k = 50 is found to be
best. Thus, all the following results are reported based on this
parameter setting.
Comparison Baselines. We compare our method with the
following baseline algorithms that were developed to deal with
multi-modality data and (or) multiple labels.
• Feature Concatenation (FC): treating our problem as sev-
eral independent binary classification problems solved via
linear SVMs trained using only the observed symptoms
(i.e., as discussed in Section IV).
• Sparse Multimodal Biometrics Recognition (SMBR)
[25]: a joint sparse representation for multi-modality data.
• Binary Relevance (BR) [5]: learning several independent
binary classifiers for multi-label learning.
• Calibrated Label Ranking (CLR) [13]: treating multi-
label learning task as a typical label ranking problem.
• Rank-SVM [11]: maximizing the margin for multi-label
data by incorporating both the relevant and the irrelevant
labels.
• ML-kNN [34]: a multi-label version of traditional kNN
by maximizing the posterior probability.
• MLMVL-MM [12]: learning a multi-modality consensus
representation by imposing maximum margin criterion.
• MVML [35]: combining multiple single-label learners in
a boosting framework, with a modified multi-modality
SVM used as the base learner.
We use the publicly available implementations for SMBR3,
BR4, CLR5[32], ML-kNN6, and Rank-SVM7 in this study.
3http://users.umiacs.umd.edu/ sshekha/robustmulti.html
4http://mulan.sourceforge.net/doc/
5http://mulan.sourceforge.net/doc/
6http://cse.seu.edu.cn/PersonalPage/zhangml/files/ML-kNN.rar
7http://cse.seu.edu.cn/PersonalPage/zhangml/files/RankSVM.rar
For MLMVL-MM and MVML, as their implementations are
not publicly available, we implement them ourselves. All the
parameters in these baselines are automatically determined
by the same aforementioned process. For multi-label learning
methods (i.e., BR, CLR, ML-kNN, Rank-SVM), we combine
the observed motor and non-motor symptoms (two modalities)
into a feature matrix (X in Section III) during the learning
process.
Please also note that, we did not include the similarity-based
representations for these multi-label learning methods, as their
results are inferior to the results that only use the feature-
based representation. Furthermore, since SMBR is specifically
designed for single label prediction, we perform SMBR for
each drug separately, and combine all the predictions as final
results.
B. Comparison with Baselines
Table III shows the prediction performance of our method
(PALAS) and the baseline methods. Note that, we choose
the PALAS (k=50) in Table III as our final model which is
used as the reference for all the comparison in the following
evaluation (including the pair-wise t-test). From the table, it
can be seen that our PALAS model (i.e., PALAS (k=50) in
Table III) outperforms all the baseline methods in all the four
evaluation metrics, except for the Ranking loss metric,
where the ML-kNN performs as well as ours.
Besides, we also conduct the pair-wise t-test between the
results from PALAS and the results from all the baseline
methods. The statistical test shows that the PALAS model is
statistically better than all the comparison methods (except
ML-kNN, if using the Ranking loss evaluation metric).
Also, we introduce the setting of our method directly trained
on the original two-view features (i.e., motor and non-motor),
and name this setting as PALAStv (k=50) in Table III. The
statistical comparison on Hamming loss was conducted and
p-values were reported in Table IV, which demonstrated that
our PALAS was statistically better than these baselines.
Please note that we also report the results of PALAS when
the latent symptoms number equals to 60 for reference (i.e.,
PALAS (k=60) in Table III).
In addition, we degenerate our PALAS model (i.e., PALAS
(k=50) in Table III) to its non-transductive version, namely
PALASwt (i.e., PALASwt (k=50) in Table III). This can
be realized by removing J in Eq. (1) and only using the
training samples to learn P. The comparison results reported
in Table III show that a slight performance improvement can
be achieved under the transductive setting. From the table, we
also note that, without the transductive setting, the standard
8TABLE III: Performance of the prescription drug prediction between our proposed method (i.e., PALAS) and the related
baseline methods. ↓ indicates the lower the better, and ↑ indicates the higher the better.
Method FC BR CLR ML-kNN Rank-SVM SMBR
Hamming loss↓ 0.574 ± 0.032 0.210 ± 0.024 0.195 ± 0.021 0.175 ± 0.016 0.184 ± 0.026 0.241 ± 0.015
One-error↓ 0.536 ± 0.140 0.283 ± 0.127 0.264 ± 0.115 0.250 ± 0.107 0.260 ± 0.125 0.292 ± 0.095
Coverage↓ 0.655 ± 0.095 0.406 ± 0.078 0.417 ± 0.063 0.364 ± 0.070 0.365 ± 0.067 0.336 ± 0.051
Ranking loss↓ 0.102 ± 0.007 0.033 ± 0.003 0.033 ± 0.001 0.023 ± 0.003 0.028 ± 0.006 0.046 ± 0.008
Sensitivity ↑ 0.657 ± 0.004 0.794 ± 0.002 0.785 ± 0.002 0.823 ± 0.002 0.817 ± 0.002 0.774 ± 0.003
Specificity ↑ 0.934 ± 0.002 0.970 ± 0.002 0.998 ± 0.001 0.996 ± 0.001 0.965 ± 0.001 0.998 ± 0.001
Accuracy ↑ 0.884 ± 0.005 0.943 ± 0.003 0.947 ± 0.002 0.969 ± 0.003 0.953 ± 0.003 0.942 ± 0.003
Method MLMVL-MM MVML PALAS (k=50) PALASwt (k=50) PALAS (k=60) PALAStv (k=50)
Hamming loss↓ 0.173 ± 0.012 0.195 ± 0.028 0.168 ± 0.017 0.169 ± 0.020 0.169 ± 0.017 0.172 ± 0.017
One-error↓ 0.231 ± 0.093 0.271 ± 0.133 0.221 ± 0.110 0.226 ± 0.121 0.240 ± 0.109 0.228 ± 0.142
Coverage↓ 0.325 ± 0.063 0.341 ± 0.081 0.320 ± 0.065 0.324 ± 0.073 0.308 ± 0.065 0.324 ± 0.088
Ranking loss↓ 0.028 ± 0.004 0.031 ± 0.008 0.026 ± 0.006 0.026 ± 0.008 0.023 ± 0.006 0.026 ± 0.006
Sensitivity ↑ 0.827 ± 0.003 0.793 ± 0.003 0.841 ± 0.002 0.839 ± 0.002 0.837 ± 0.002 0.825 ± 0.002
Specificity ↑ 0.998 ± 0.001 0.984 ± 0.002 0.999 ± 0.000 0.998 ± 0.001 0.999 ± 0.001 0.997 ± 0.001
Accuracy ↑ 0.976 ± 0.002 0.945 ± 0.003 0.983 ± 0.002 0.979 ± 0.002 0.982 ± 0.002 0.978 ± 0.003
(a) Prediction: β=10−5 (b) Prediction: β=10−3
(c) Prediction: β=0.1 (d) Ground Truth
Fig. 6: The role of β. From top left to bottom right correspond to the predicted drug label matrices with β=10−5, β=10−3, and
β=0.1, and the ground truth label matrix, respectively. Rows indicate different drugs, and columns indicate different patients.
White dot means the corresponding patient takes the corresponding drug, while black dot means not. Larger β value will
resulting to sparser predicted results.
deviation of PALASwt is generally slightly higher than that of
PALAS, implying that the transductive setting has more stable
performance.
TABLE IV: The p-values of PALAS against other methods on
Hamming loss.
PALAS against Method p-values Is significantly better?
FC 6.21× 10−15 X
BR 3.74× 10−13 X
CLR 2.85× 10−4 X
ML-kNN 7.73× 10−3 X
Rank-SVM 9.61× 10−4 X
SMBR 9.47× 10−9 X
MLMVL-MM 7.44× 10−3 X
MVML 3.65× 10−4 X
Compared with MLMVL-MM and PALAS (i.e., PALAS
(k=50) in Table III), MVML ignores the relation among
different drugs as it directly models the (multiple label)
learning task as a combination of several single-label learning
problems. The result in Table III shows that, the relation of
multiple labels can be well used for performance improvement
for MLMVL-MM and PALAS. Moreover, by comparing with
(single-modality) multiple label learning methods, we can infer
that multi-modality setting of learning the intrinsic representa-
tion across different modalities could help guide better results.
Finally, the confusion matrix of all 31 drugs is provided in
Figure 7.
C. Sensitivity Analysis
For a better understanding of our proposed PALAS model,
taking PALAS (k=50) in Table III as an example, we investi-
gate how the parameter setting and the tranductive component
affect its performance. First, we investigate the influence of
the parameter k, i.e., the dimension of the latent space. Figure
5 shows the model performance by varying different number
of k values, from 10 to 100. Here, α and β are automatically
determined by the given k which follows the same parameter
selection process as that in Section V-A: the combination of
α and β that achieves lowest value in Hamming loss on a
randomly-chosen testing set (by randomly sampling 10% data
from the dataset) is selected.
From Figure 5, it is observed that the setting k = 50
leads to better Hamming loss and One-error, while
the setting k = 60 leads to better Ranking loss and
Coverage. In addition, we can see that small value of k will
9result to poor performance, which is understandable as that
latent space cannot fully capture the relationship between the
observed symptoms and the prescription drugs. On the other
hand, setting the value of k too large will also decline the
performance, probably due to the noise and overfitting issues
that start to kick in for high dimensional data.
Next, we investigate the influence of the parameter β,
which is used to control the sparsity of the symptom-to-drug
transformation matrix V in Eq. (1). This sparsity constraint
is reasonable as most patients would only take a very few
from all the candidates of treatment drugs, instead of being
prescribed all kinds of treatment drugs, as shown in Figure
6(d). Thus, we visually investigate the final predicted drug
label matrix by using different values of β, as shown in
Figure 6. From the figure, we can observe that the larger the
value of β, the sparser the predicted label matrix, in which at
the β = 0.1, the sparse predicted label matrix (Figure 6(c))
closely resembles the ground truth label matrix (Figure 6(d)).
Thus, imposing sparsity constraint on V will likely benefit the
predicted results.
Furthermore, to investigate the sensitivity of the PALAS
model to the weight parameters (i.e., α and β), we show the
performance of the PALAS model using different combina-
tions of α and β in Figure 8. Please note that, for simplicity,
the values 1 to 15 in the x and y axes actually denote the
corresponding indices of the aforementioned 15 values (i.e.,
1, 0.5, 0.3, 0.1, 0.05, 0.01, 0.005, 0.001, 5 × 10−4, 10−4,
5× 10−5, 10−5, 10−6, 10−8, 10−10).
D. Clinical Explanation and Discussion
The evaluation metrics that we used so far (i.e., Hamming
loss, One-error, Coverage, and Ranking loss) are
originally designed to evaluate performance of multi-label
prediction. We use these metrics as the reference from the
data-driven perspective.
We now report the evaluation from the clinical perspective.
Specifically, we have asked three experienced neurologists
to double-check with the predicted results (e.g., the third
prediction results in Figure 6). Specifically, the neurologists
are asked to determine whether the predicted drugs can im-
prove the observed symptoms of a patient from the clinical
perspective. A prescription prediction is said to be correct
if more than 2 in 3 neurologists agree it will improve PD,
otherwise the prescription prediction is regarded as incorrect.
This evaluation enables us to calculate the overall clinical
accuracy as shown in Figure 9. For the prediction of 136
patients, PALAS achieves 87.5% accuracy (i.e., 119 correct
and 17 incorrect), outperforms all the competitive methods
(i.e., SMBR, BR, CLR, ML-kNN, Rank-SVM, MLMVL-MM
and MVML).
In addition, we found that the incorrect prediction mostly
happens for the prescription drug of non-motor symptoms.
This could be due to the fact that, compared with motor-
symptoms, the non-motor symptoms are more difficult to be
accurately quantized.
For the limitation of our current study, firstly, the proposed
method requires all the records (i.e., motor and non-motor
symptoms) are completed. However, in some cases, we might
encounter the data missing problem during recoding these
symptoms. Secondly, for new coming data, we need to retrain
our model by mixing the existed and new collected data. A
better way is to design an online algorithm to update the
learned model without retraining. Finally, a more interpretable
way could be developed to enhance the current data-driven
prediction. For these aforementioned issues, we will carefully
consider in our future work. Also, in our future work, the
threats-to-validity of our prediction results on a large popula-
tion group will be designed and conducted.
For the setting of supervised and transductive learning, from
Table III, we observe that the advantage of transductive setting
is that it has a slight performance improvement with lower
standard deviation compared with supervised setting. However,
its disadvantage comes from that for the new testing data,
transductive setting is required to re-train the model. In this
paper, we introduce these two settings to fully understand our
method: 1) for the small sample-sized problem, transductive
setting is preferable since re-training does not waste too much
time and 2) for the large sample-sized problem, we will
directly use supervised setting.
We wish to clarify that, whether or not the learned latent
connections represent real causal relationships is beyond the
consideration of the model/algorithm. That’s exactly why the
presence of experienced neurologists is still a must in practice.
The model/algorithm should be regarded as an assistant to neu-
rologists, recommending a good initial therapy from the data-
driven perspective. It is still the neurologists’ responsibility to
treat the patients properly.
For possible clinical application, the proposed method could
be potentially employed in several scenario. The main scenario
is that when the neurologists have disagreement on selection
of drugs, the proposed method could provide a reference from
data-driven perspective. Also, our method has its advantage
to be extended to other important scenario: 1) A correlation
study between patients and drugs can be further investigated
to deeply understand different drug preference. 2) Different
alternatives of drug recommendation from various aspects (by
using different costs, e.g., number, price) can be generated
together to aid neurologist during decision making.
VI. CONCLUSION
We study a novel problem in this paper, i.e., computer-
aided prescription for PD, aiming to predict the suitable
treatment drugs according to the observed motor and non-
motor symptoms of a PD patient. The highlights of our work
include: (1) our method is the first attempt to study the
automatic prescription prediction for PD patient, (2) we adopt
the multi-modality representation to incorporate various repre-
sentations for better prediction performance, (3) the proposed
PALAS model is able to capture the intrinsic symptom-to-drug
relationship. Experimental results validate the effectiveness of
our method compared with other related baseline methods.
Our future directions include: (1) using wearable sensors
to automatically record more information, (2) employing new
modality (e.g., eye-tracker) to investigate personal habit of
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Fig. 7: The confusion matrix of different prescription drug.
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Fig. 8: The results of choosing different combinations of α and β. Top left to bottom right: the results of Hamming loss,
One-error, Coverage, and Ranking loss.
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Fig. 9: The clinical accuracy of prescription prediction (eval-
uated by three neurologists) using different methods.
patients, and (3) designing an on-line learning strategy to
incorporate new PD patients and the corresponding human-
based prescription records, without re-training the current
model.
REFERENCES
[1] Ehsan Adeli, Feng Shi, Le An, Chong-Yaw Wee, Guorong Wu, Tao Wang,
and Dinggang Shen. Joint feature-sample selection and robust diagnosis
of parkinson’s disease from MRI data. NeuroImage, 141:206 – 219, 2016.
[2] Francis R. Bach, Gert R.G. Lanckriet, and Michael I. Jordan. Multiple
kernel learning, conic duality, and the smo algorithm. In ICML, pages
6–14, 2004.
[3] Amir Beck and Marc Teboulle. A fast iterative shrinkage-thresholding
algorithm for linear inverse problems. SIAM J. Img. Sci., 2(1):183–202,
March 2009.
[4] Avrim Blum and Tom Mitchell. Combining labeled and unlabeled data
with co-training. In COLT, pages 92–100, 1998.
[5] Matthew R. Boutell, Jiebo Luo, Xipeng Shen, and Christopher M. Brown.
Learning multi-label scene classification. Pattern Recognition, 37(9):1757
– 1771, 2004.
[6] Jiayue Cai, Aiping Liu, Taomian Mi, Saurabh Garg, Wade Trappe, Martin
J. McKeown, and Z. Jane Wang. Dynamic Graph Theoretical Analysis
of Functional Connectivity in Parkinson’s Disease: The Importance of
Fiedler Value. IEEE Journal of Biomedical and Health Informatics,
23(4):1720–1729, 2019.
[7] Carlotta Caramia, Diego Torricelli, Maurizio Schmid, Adriana Munoz-
Gonzalez, Jose Gonzalez-Vargas, Francisco Grandas, and Jose L. Pons.
11
IMU-Based Classification of Parkinson’s Disease From Gait: A Sensitiv-
ity Analysis on Sensor Location and Feature Selection. IEEE Journal of
Biomedical and Health Informatics, 22(6):1765–1774, 2018.
[8] Amanda Clare and Ross D. King. Knowledge discovery in multi-label
phenotype data. Lecture Notes in Computer Science, 2168(2168):42–53,
2002.
[9] Juan Camilo Vasquez-Correa, Tomas Arias-Vergara, J.R. Orozco-
Arroyave, Bjorn Eskofier, Jochen Klucken, and Elmar Noth. Multimodal
Assessment of Parkinson’s Disease: A Deep Learning Approach. IEEE
Journal of Biomedical and Health Informatics, 23(4):1618–1630, 2019.
[10] Yijie Ding, Jijun Tang, and Fei Guo. Identification of Drug-Side Effect
Association via Semisupervised Model and Multiple Kernel Learning.
IEEE Journal of Biomedical and Health Informatics, 23(6):2619–2632,
2019.
[11] Andre Elisseeff and Jason Weston. A kernel method for multi-labelled
classification. In NIPS, pages 681–687. MIT Press, 2001.
[12] Zheng Fang and Zhongfei Zhang. Simultaneously combining multi-view
multi-label learning with maximum margin classification. In ICDM, pages
864–869, Dec 2012.
[13] Johannes Fu¨rnkranz, Eyke Hu¨llermeier, Eneldo Loza Mencı´a, and Klaus
Brinker. Multilabel classification via calibrated label ranking. Mach.
Learn., 73(2):133–153, November 2008.
[14] David R. Hardoon and John Shawe-Taylor. Convergence analysis of
kernel canonical correlation analysis: Theory and practice. Mach. Learn.,
74(1):23–38, January 2009.
[15] Thomas J. Hirschauer, Hojjat Adeli and John A. Buford. Computer-
aided diagnosis of parkinson’s disease using enhanced probabilistic neural
network. Journal of Medical Systems, 39(11):179, 2015.
[16] Haijun Lei, Zhongwei Huang, Feng Zhou, Ahmed Elazab, Ee-Leng Tan,
Hancong Li, Jing Qin, and Baiying Lei. Parkinson’s Disease Diagnosis
via Joint Learning From Multiple Modalities and Relations. IEEE Journal
of Biomedical and Health Informatics, 23(4):1437–1449, 2019.
[17] Rui Li, Ping Wu, Igor Yakushev, Jian Wang, Sibylle I. Ziegler, Stefan
Fo¨rster, Sung-Cheng Huang, Markus Schwaiger, Nassir Navab, Chuantao
Zuo, and Kuangyu Shi. Pattern visualization and recognition using tensor
factorization for early differential diagnosis of parkinsonism. In MICCAI,
pages 125–133, 2017.
[18] Wenzhao Lian, Piyush Rai, Esther Salazar, and Lawrence Carin. In-
tegrating features and similarities: flexible models for heterogeneous
multiview data. In AAAI, 2015.
[19] Ning Liu, Cheng-Bang Chen, and Soundar Kumara. Semi-Supervised
Learning Algorithm for Identifying High-Priority DrugCDrug Interactions
Through Adverse Event Reports. IEEE Journal of Biomedical and Health
Informatics, 24(1):57–68, 2020.
[20] Luyan Liu, Qian Wang, Ehsan Adeli, Lichi Zhang, Han Zhang, and
Dinggang Shen. Feature selection based on iterative canonical correlation
analysis for automatic diagnosis of parkinson’s disease. In MICCAI, pages
1–8, 2016.
[21] Francisco Oliveira and Miguel Castelo-Branco. Computer-aided diagno-
sis of Parkinson’s disease based on spect binding potential images using
the voxels-as-features approach and support vector machines. Journal of
Neural Engineering, 12(2):026008, 2015.
[22] Novi Quadrianto and Christoph H. Lampert. Learning multi-view
neighborhood preserving projections. In ICML, pages 425–432, 2011.
[23] Alain Rakotomamonjy, Francis Bach, Stephane Canu, and Yves Grand-
valet. SimpleMKL. Journal of Machine Learning Research, 9:2491–2521,
2008.
[24] Ali Samii, John G Nutt, and Bruce R Ransom. Parkinson’s disease. The
Lancet, 363:1783–1793, 2004.
[25] Sumit Shekhar, Vishal M. Patel, Nasser M. Nasrabadi, and Rama
Chellappa. Joint sparse representation for robust multimodal biomet-
rics recognition. IEEE Transactions on Pattern Analysis and Machine
Intelligence, 36(1):113–126, Jan 2014.
[26] Yinghuan Shi, Yang Gao, Yubin Yang, Ying Zhang, and Dong
Wang. Multimodal sparse representation-based classification for lung
needle biopsy images. IEEE Transactions on Biomedical Engineering,
60(10):2675 – 2685, 2013.
[27] Yinghuan Shi, Heung-Il Suk, Yang Gao, and Dinggang Shen. Joint
coupled-feature representation and coupled boosting for AD diagnosis.
In IEEE CVPR, page 2721, 2014.
[28] Yinghuan Shi, Heung-Il Suk, Yang Gao, Seong-Whan Lee, and Ding-
gang Shen. Leveraging Coupled Interaction for Multi-Modal Alzheimers
Disease Diagnosis. In IEEE Trans. on Neural Networks and Learning
Systems, 31(1):186 – 200, 2020.
[29] Yinghuan Shi, Yaozong Gao, Shu Liao, Daoqiang Zhang, Yang Gao, and
Dinggang Shen. Semi-Automatic Segmentation of Prostate in CT Images
via Coupled Feature Representation and Spatial-Constrained Transductive
Lasso. IEEE Transactions on Pattern Analysis and Machine Intelligence,
37(11):2286–2303, Apr 2015.
[30] Vikas Sindhwani and David S. Rosenberg. An RKHS for multi-view
learning and manifold co-regularization. In ICML, pages 976–983, New
York, NY, USA, 2008. ACM.
[31] Gurpreet Singh and Lakshminarayanan Samavedham. Unsupervised
learning based feature extraction for differential diagnosis of neurode-
generative diseases: A case study on early-stage diagnosis of parkinson
disease. Journal of Neuroscience Methods, 256:30–40, 2015.
[32] Grigorios Tsoumakas, Eleftherios Spyromitros-Xioufis, Jozef Vilcek,
and Ioannis Vlahavas. Mining Multi-label Data. Data Mining and
Knowledge Discovery Handbook, O. Maimon, L. Rokach (Ed.), Springer,
2nd edition, 2010.
[33] Chang Xu, Dacheng Tao, and Chao Xu. A survey on multi-view learning.
CoRR, abs/1304.5634, 2013.
[34] Min-Ling Zhang and Zhi-Hua Zhou. ML-kNN: A lazy learning approach
to multi-label learning. Pattern Recogn., 40(7):2038–2048, July 2007.
[35] Fuhao Zou, Yu Liu, Hua Wang, Jingkuan Song, Jie Shao, Ke Zhou,
and Sheng Zheng. Multi-view multi-label learning for image annotation.
Multimedia Tools and Applications, 75(20):12627–12644, 2016.
[36] D. Zhang, Y. Wang, L. Zhou, H. Yuan, and D. Shen, “Multimodal
classification of Alzheimer’s disease and mild cognitive impairment,”
NeuroImage, vol. 55, no. 3, pp. 856–867, 2011.
[37] B. Jie, M. Liu, D. Zhang, and D. Shen, “Sub-network kernels for
measuring similarity of brain connectivity networks in disease diagnosis,”
IEEE Transactions on Image Processing, vol. 27, pp. 2340–2353, 2018.
[38] W. Zhang, T. Luo, S. Qiu, J. Ye, D. Cai, X. He, and J. Wang,
“Identifying genetic risk factors for Alzheimer’s disease via shared tree-
guided feature learning across multiple tasks,” IEEE TKDE, 2018, doi:
10.1109/TKDE.2018.2816029.
[39] J. Xu, C. Deng, X. Gao, D. Shen, and H. Huang, “Predicting Alzheimer’s
disease cognitive assessment via robust low-rank structured sparse
model,” in IJCAI, 2017.
[40] J. Kim and B. Lee, “Identification of alzheimer’s disease and mild cog-
nitive impairment using multimodal sparse hierarchical extreme learning
machine,” Human Brain Mapping, vol. 39, no. 9, pp. 3728–3741, 2018.
[41] T. Tong, K. Gray, Q. Gao, L. Chen, and D. Rueckert, “Multi-modal
classification of alzheimer’s disease using nonlinear graph fusion,” Pattern
Recognition, vol. 63, pp. 171 – 181, 2017.
[42] K. Linda, F. David, B. Nada, A. Mahnaz, “The characteristics and
treatment patterns of patients with Parkinson’s disease in the United States
and United Kingdom: A retrospective cohort study,” PLOS ONE, vol. 14,
no. 11, 2019.
[43] J. Almeida, P. Reboucas Filho, T. Carneiro, W. Wei, et al ., “Detecting
Parkinson’s disease with sustained phonation and speech signals using
machine learning techniques,” Pattern Recognition Letters, vol. 125, pp.
55 – 62, 2019.
[44] A. Lauraitis and R. Maskeliunas and R. Damasevicius and D. Polap
and M. Wozniak, “A Smartphone Application for Automated Decision
Support in Cognitive Task Based Evaluation of Central Nervous System
Motor Disorders,” IEEE Journal of Biomedical and Health Informatics,
vol. 23, no. 5, pp. 1865 – 1876, 2019.
[45] https://www.apdaparkinson.org/what-is-parkinsons/
treatment-medication/medication/.
[46] Chen et al ., “The recommendations of Chinese Parkinsons disease
and movement disorder society consensus on therapeutic management
of Parkinsons disease. Transl Neurodegener,” PLOS ONE, vol. 5, no. 12,
2016.
[47] G. Wu, F. Qi, D. Shen, “Learning-based deformable registration of MR
brain images,” IEEE transactions on Medical Imaging, vol. 25, no. 9, pp.
1145 – 1157, 2006.
[48] Y. Fan, RE. Gur, RC. Gur, X. Wu, D. Shen, ME. Calkins, C. Davatzikos,
“Unaffected family members and schizophrenia patients share brain struc-
ture patterns: a high-dimensional pattern classification study,” Biological
psychiatry, vol. 63, no. 1, pp. 11 – 124, 2008.
[49] Y. Fan, et al ., “Multivariate examination of brain abnormality using
both structural and functional MRI,” NeuroImage, vol. 36, no. 4, pp. 119
– 1199, 2007.
[50] T. Zhou, M. Liu, K. Thung, D. Shen, “Latent representation learning for
Alzheimers disease diagnosis with incomplete multi-modality neuroimag-
ing and genetic data,” IEEE transactions on Medical Imaging, vol. 38,
no. 10, pp. 2411 – 2422, 2019.
[51] T. Zhou, H. Fu, G. Chen, J. Shen, L. Shao “Hi-net: hybrid-fusion
network for multi-modal MR image synthesis,” IEEE transactions on
Medical Imaging, doi: 10.1109/TMI.2020.2975344, 2020.
